Our top pick for
Arcus Biosciences, Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 139 staff and has a trailing 12-month revenue of around USD$77.8 million.
Since the stock market crash in March caused by coronavirus, Arcus Biosciences's share price has had significant positive movement.
Its last market close was USD$22.68, which is 23.63% up on its pre-crash value of USD$17.32 and 151.02% up on the lowest point reached during the March crash when the shares fell as low as USD$9.035.
If you had bought USD$1,000 worth of Arcus Biosciences shares at the start of February 2020, those shares would have been worth USD$1,138.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,459.87.
|Latest market close||USD$22.68|
|52-week range||USD$7.69 - USD$37.41|
|50-day moving average||USD$21.5729|
|200-day moving average||USD$23.8558|
|Wall St. target price||USD$37.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.589|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||N/A|
|1 month (2020-10-30)||4.04%|
|3 months (2020-08-26)||N/A|
|6 months (2020-05-26)||N/A|
|1 year (2019-11-26)||N/A|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$77.8 million|
|Gross profit TTM||USD$-63,481,000|
|Return on assets TTM||-10.91%|
|Return on equity TTM||-24.28%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 6.6 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 5.3% down from 7.0 million last month.
There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.
Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 599883.55916893). Arcus Biosciences's SIR currently stands at 11.07. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 11070 shares are currently held short.
However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 100 shares are currently held short) or 0.1288% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 129 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arcus Biosciences.
Find out more about how you can short Arcus Biosciences stock.
We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $7.69 up to $37.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.1854. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. The company was founded in 2015 and is based in Hayward, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.